Drug glucuronidation in clinical psychopharmacology

Journal of Clinical Psychopharmacology

Volumn 21, Issue 5, 2001, Pages 500-515

  Liston, Heidi L ^a   Markowitz, John S ^b   DeVane, C Lindsay ^a,b,c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BUPRENORPHINE; CYTOCHROME P450 ISOENZYME; DAPSONE; DOBUTAMINE; DOPAMINE RECEPTOR; ETHINYLESTRADIOL; GLUCURONOSYLTRANSFERASE; GLYCERYL TRINITRATE; HYDRALAZINE; IRINOTECAN; ISONIAZID; LAMOTRIGINE; LEVODOPA; LORAZEPAM; MERCAPTOPURINE; METHYLDOPA; MORPHINE; NALORPHINE; NALTREXONE; NORADRENALIN; OLANZAPINE; OXAZEPAM; PARACETAMOL; PHENELZINE; PROCAINAMIDE; SALBUTAMOL; TERBUTALINE; UNINDEXED DRUG; VALPROIC ACID;

AGE; ARTICLE; CIGARETTE SMOKING; CLINICAL PHARMACOLOGY; DRUG COMPETITION; DRUG GLUCURONIDATION; ENZYME REGULATION; ENZYME SUBSTRATE; HUMAN; MEDICAL LITERATURE; OBESITY; PRIORITY JOURNAL; PROTEIN FAMILY; PSYCHOPHARMACOLOGY; REGULATORY MECHANISM; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; GLUCURONATES; GLUCURONOSYLTRANSFERASE; HUMANS; INFANT; MALE; MENTAL DISORDERS; MIDDLE AGED; PSYCHOPHARMACOLOGY; PSYCHOTROPIC DRUGS;

EID: 0034796041     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200110000-00008     Document Type: Article

References (155)

1. Metabolic changes of drugs and related organic compounds
2. Cytochromes in psychopharmacology
3. Newer antidepressants and the cytochrome P450 system
4. Glucuronidation of drugs, a re-evaluation of the pharmacological significance of the conjugates and modulating factors
5. Drug glucuronidation in humans
6. Mechanism of anticonvulsant action of valproate
7. Haloperidol metabolism in psychiatric patients: Importance of glucuronidation and carbonyl reduction
8. Disposition and biotransformation of the antipsychotic agent olanzapine in humans
9. Characterization of phase I and phase II hepatic drug metabolism activities in a panel of human liver preparations
10. Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation
11. Isolation and characterization of a novel quaternary ammonium-linked glucuronide of lamotrigine
12. Substrate specificities of two stably expressed human liver UDP-glucuronosyltransferases of the UGT1 gene family
13. Expressed human UGT1.4 protein catalyzes the formation of quaternary ammonium-linked glucuronides
14. Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3
15. Glucuronidation of amine substrates by purified and expressed UDP-glucuronosyltransferase proteins
16. Olanzapine 10-N-glucuronide, a tertiary N-glucuronide unique to humans
17. +-glucuronidation of aliphatic tertiary amines in human: Antidepressant versus antipsychotic drugs
18. Morphine-6-glucuronide, a potent MU agonist
19. Positive inotropic effects of digitoxin- and digoxin-glucuronide in human isolated ventricular heart muscle preparations
20. Antitumor activity of methyl (5-fluoro-1H-2-oxo-4-pyrimidinyl β-D-glucopyranosid) uronate against various experimental tumors
21. Morphine and metabolite behavior after different routes of morphine administration: Demonstration of the importance of the active metabolite morphine-6-glucuronide
22. Morphine metabolism in man
23. Pharmacokinetics and pharmacodynamics of morphine-3-glucuronide in rats and its influence on the antinociceptive effect of morphine
24. Acyl glucuronides revisited: Is the glucuronidation process a toxification as well as a detoxification mechanism?
25. Irreversible binding of zomepirac to plasma protein in vitro and in vivo
26. In vitro evidence for the involvement of at least two forms of human liver UDP-glucuronosyltransferase in morphine 3-glucuronidation
27. Stereoselective disposition of racemic E-10-hydroxynortriptyline in human beings
28. (S)oxazepam glucuronidation is inhibited by ketoprofen and other substrates of UGT2B7
29. Human liver morphine UDP-glucuronyl transferase enantioselectivity and inhibition by opioid congeners and oxazepam
30. Stereospecific benzodiazepine receptor binding by the enantiomers of oxazepam sodium hemisuccinate
31. Glucuronidation: A dual control
32. Structure and function of uridine diphosphate glucuronosyltransferases
33. The UDP glycosyltransferase gene superfamily: Recommended nomenclature update based on evolutionary divergence
34. Cloning and stable expression of a new member of the human liver phenol/bilirubin: UDP-glucuronosyltransferase cDNA family
35. Diversity and independent regulation at the novel human UGTI locus encoding 12 UDP-glucurono-syltransferase isozymes through duplication of both exon 1 and the upstream regulatory region
36. A novel complex locus UGTI encodes human bilirubin, phenol and other UDP-glucuronosyl-transferase isozymes with identical carboxyl termini
37. Investigation of the substrate specificity of a cloned expressed human bilirubin UDP-glucurono-syltransferase: UDP-sugar specificity and involvement in steroid and xenobiotic glucuronidation
38. cDNA cloning and characterization of the human UDP glucuronosyltransferase, UGT1A3
39. Functions and transcriptional regulation of pah-inducible human UDP-glucuronosyl-transferases
40. UDP-glucuronosyl-transferase activity in human liver and colon
41. Cloning and expression of human UDP-glucuronosyltransferase (UGT) 1A8
42. Drug metabolism in pregnancy, infancy, and childhood
43. The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-glucuronosyltransferase 1.1
44. Severe CPT-11 toxicity in patients with Gilbert's syndrome: Two case reports
45. Genetic predisposition to the metabolism of irinotecan (CPT-11)-role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes
46. Glucuronidation of catechol estrogens by expressed human UDP-glucuronosyltransferases (UGTs) 1A1, 1A3, and 2B7
47. Glucuronidation of amines and hydroxylated xenobiotics and endobiotics catalyzed by expressed human UGT1.4 protein
48. Retigabine N-glucuronidation and its potential role in enterohepatic circulation
49. Paracetamol glucuronidation by recombinant rat and human phenol UDP-glucuronosyltransferases
50. UDP-glucuronosyltransferases and their role in metabolism and disposition of carcinogens
51. Glucuronidation of carcinogenic arylamines and their N-hydroxy derivatives by rat and human phenol UDP-glucuronosyltransferases of the UGT1 gene complex
52. Expression of UDP-glucuronosyltransferases (UGTs) 2B7 and 1A6 in the human brain and identification of 5-hydroxytryptamine as a substrate
53. Isolation of a human YAC contig encompassing a cluster of UGT2 genes and its regional localization to chromosome 4q 13
54. Localization of a bile acid UDP-glucuronosyltransferase gene (UGT2B) to chromosome 4 using the polymerase chain reaction
55. Odorant signal termination by olfactory UDP-glucuronosyltransferase
56. Human UGT2B7 catalyzes morphine glucuronidation
57. The glucuronidation of opioids, other xenobiotics and androgens by human UGT2B7Y(268) and UGT2B7H(268)
58. Characterization of a cloned human dihydrotestosterone/androstanediol UDP-glucuronosyltrans-ferase and its comparison to other steroid isoforms
59. Induction of human UDP glucuronosyltransferases (UGT1A6, UGT1A9, and UGT2B7) by t-butylhydroquinone and 2,3,7,8-tetrachlorodibenzo-p-dioxin in cao-2 cells
60. UDP-glucurono-syltransferases in human intestinal mucosa
61. Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs
62. Human brain metabolism of morphine and naloxone
63. Stable expression of human liver and UDP-glucuronosyltransferase (UGT2B15) with activity toward steroid and xenobiotic substrates
64. 85): A UDP-glucuronosyltransferase encoded by a polymorphic gene
65. Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome
66. Genetic defects at the UGT1 locus associated with Crigler-Najjar type I disease, including a prenatal diagnosis
67. UGT1*1 genotyping in a Canadian Inuit population
68. The UGT1A1*28 allele is relatively rare in a Japanese population
69. Ethnic differences in glucuronidation of nicotine and cotinine
70. Differences in the urinary metabolites of the tobacco-specific lung carcinogen 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone in black and white smokers
71. Interindividual and interethnic differences in the demethylation and glucuronidation of codeine
72. Environmental factors affecting paracetamol metabolism in London factory and office workers
73. Navajo jaundice: A variant of neonatal hyperbilirubinemia associated with breast feeding
74. The maturation of morphine clearance and metabolism
75. The pharmacokinetics of chloramphenicol in the neonate and young infant
76. Pharmacokinetics of acetaminophen in the human neonate: Formation of acetaminophen glucuronide and sulfate in relation to plasma bilirubin concentration and D-glucaric acid excretion
77. Chloramphenicol and the neonate - 1979 View
78. The effect of age on glucuronidation and sulphation of paracetamol by human liver fractions
79. Oxazepam kinetics: Effects of age and sex
80. Effect of age and gender on disposition of temazepam
81. Codeine metabolism and disposition: Comparison in young and elderly subjects
82. Single dose pharmacokinetic and pharmacodynamics of oral oxazepam in very elderly institutionalized subjects
83. Obesity, sex, and acetaminophen disposition
84. Influence of sex and oral contraceptive steroids on paracetamol metabolism
85. The influence of environmental and genetic factors on CYP2D6, CYP1A2, and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes
86. Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects
87. Dose-related plasma levels of clozapine: Influence of smoking behavior, sex, and age
88. Combined population analysis of olanzapine in healthy volunteers
89. Predicting drug interactions and pharmacokinetic variability with in vitro methods: The olanzapine experience
90. Enhanced glucuronide conjugation of drugs in obesity: Studies of lorazepam, oxazepam, and acetaminophen
91. Decreased chloramphenicol clearance in malnourished ethiopian children
92. Glucuronidation of drugs by hepatic microsomes derived from healthy and cirrhotic human livers
93. Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism
94. Abnormalities in the metabolism of acetaminophen in patients infected with the human immunodeficiency virus (HIV)
95. Induction of cytochrome P-448 iso-enzymes and related glucuronyltransferases in the human liver by cigarette smoking
96. Selective induction of propranolol metabolism by smoking: Additional effects on renal clearance of metabolites
97. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: Effect of smoking
98. Interaction of alcohol with other drugs and nutrients: Implications for the therapy of alcoholic liver disease
99. UDP-glucuronosyltransferase inhibitors
100. Clinical pharmacokinetics of paracetamol
101. Active hydroxymetabolites of antidepressants. Emphasis on E-10-hydroxy-nortriptyline
102. Glucuronidation of the enantiomers of E-10-hydroxy-nortriptyline in human and rat liver microsomes
103. Tricyclic antidepressants inhibit opioid receptor binding in human brain and hepatic morphine glucuronidation
104. Glucuronidation of codeine and morphine in human liver and kidney microsomes: Effect of inhibitors
105. Antidepressants increase bioavailability of morphine in cancer patients
106. Studies on the effects of antidepressant drugs on the antinociceptive action of morphine and on plasma morphine in rat and man
107. Inhibition of human and rabbit liver steroid and xenobiotic UDP-glucuronosyltransferases by tertiary amine drugs - Implications for adverse drug reactions
108. Lamotrigine toxicity secondary to sertraline
109. Lamotrigine, a new anticonvulsant: Pharmacokinetics in normal humans
110. Citalopram pharmacokinetic interaction with clomipramine. UDP-glucuronosyltransferase inhibition? A case report
111. Clinical pharmacokinetics of gabapentin
112. Urinary excretion of valproate and some metabolites in chronically treated patients
113. Effect of valproate on the pharmacokinetics of lamotrigine
114. Lamotrigine-induced severe cutaneous adverse reactions
115. The mechanism of the carbamazepine-valproate interaction in humans
116. Inhibition of phenobarbitone N-glucosidation by valproate
117. Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics
118. Increase in serum clomipramine concentrations caused by valproate
119. Lorazepam-valproate interaction: Studies in normal subjects and isolated perfused rat liver
120. Effect of valproate on the pharmacokinetics and pharmacodynamics of lorazepam
121. A clinically significant interaction between clozapine and valproate
122. Potential impact of valproic acid therapy on clozapine disposition
123. Glucuronidation of 3′-azido-3′-deoxythimidine (zidovudine) by human liver microsomes: Relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, methadone, and valproic acid
124. Valproic acid increases cerebrospinal fluid zidovudine levels in a patient with AIDS
125. Effect of chronic administration of centrally acting compounds on chloramphenicol metabolism in schizophrenic patients
126. Oxazepam pharmacokinetics in patients with epilepsy treated long-term with phenytoin alone or in combination with phenobarbitone
127. Interaction between olanzapine and haloperidol
128. Effect of clozapine on plasma nortriptyline concentration
129. The pharmacologic treatment of neuroleptic-induced akathisia
130. The effect of propranolol on paracetamol metabolism in man
131. Propranolol interactions with diazepam, lorazepam, and alprazolam
132. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder
133. Pharmacokinetics metabolism of guanfacine in man: A review
134. Increased plasma valproate concentrations when coadministered with guanfacine
135. Inhibition of morphine glucuronidation by oxazepam in human fetal liver microsomes
136. Possible interaction between clozapine and lorazepam
137. Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazepam
138. Differential effects of oral contraceptive steroids on the metabolism of benzodiazepines
139. Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives
140. Stimulatory as well as inhibitory effects of ethinyloestradiol on the metabolic clearances of propranolol in young women
141. Increased metabolic clearance of acetaminophen with oral contraceptive use
142. Influence of gender on the pharmacokinetics and pharmacodynamics of drugs
143. Clinical pharmacokinetics of probenecid
144. Inhibition of acetaminophen and lorazepam glucuronidation in vitro by probenecid
145. Probenecid impairment of acetaminophen and lorazepam clearance: Direct inhibition of ether glucuronide formation
146. Comparative effects of rifampin and/or probenecid on the pharmacokinetics of temazepam and nitrazepam
147. Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex
148. Update on rifampin drug interactions, III
149. Pharmacokinetic interaction between rifampin and zidovudine
150. Influence of debrisoquin phenotype on the inducibility of propranolol metabolism
151. Loss of analgesic effect of morphine due to coadministration of rifampin
152. Pharmacokinetic interaction of clozapine and rifampicin in a forensic patient with an atypical mycobacterial infection
153. A case report of cimetidine-induced clozapine hepatotoxicity